Sarepta Therapeutics Inc
General
Total Cases17
Active Cases3
Patents131
Ratings
Experience
Grade
Trend
DCT
L1
C
PTAB
L4
A
CAFC
--
--
--
Analytics
Cases
Litigated Patents
Ratings Trends
Recent Dockets
Entered | Case | Description |
|---|---|---|
| 02/21/25 | STIPULATION TO EXTEND TIME to file a public version of the Declaration of John Jarosz (D.I. 736) to February 24, 2025 - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 02/21/2025) | |
| 02/20/25 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,441,192 B2; 8,697,443 B2. (Attachments: # [1] Order)(nms) (Entered: 02/20/2025) | |
| 02/19/25 | SO ORDERED Granting [69] Joint Stipulation for Dismissal With Prejudice (***Civil Case Terminated). Signed by Judge Richard G. Andrews on 2/19/2025. (nms) (Entered: 02/19/2025) | |
| 02/18/25 | STIPULATION of Dismissal with Prejudice by Sarepta Therapeutics, Inc.. (Farnan, Kelly) (Entered: 02/18/2025) | |
| 02/18/25 | CORRECTING ENTRY: The Notice of Service filed at D.I. 733 has been removed from the docket, as it was filed in error, per the request of counsel. (ceg) (Entered: 02/18/2025) | |
| 02/14/25 | [SEALED] DECLARATION of John C. Jarosz re [734] MOTION for Supplemental Damages and Pre- and Post Judgment Interest by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 02/14/2025) | |
| 02/14/25 | OPENING BRIEF in Support re [734] MOTION for Supplemental Damages and Pre- and Post Judgment Interest filed by Sarepta Therapeutics, Inc., The University of Western Australia.Answering Brief/Response due date per Local Rules is 2/28/2025. (Dellinger, Megan) (Entered: 02/14/2025) | |
| 02/14/25 | MOTION for Supplemental Damages and Pre- and Post Judgment Interest - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 02/14/2025) | |
| 02/14/25 | NOTICE OF SERVICE of (1)Plaintiffs' Responses and Objections to Dexcel's Notices of Rule 30(b)(6) Depositions; and (2) Plaintiffs' First Supplemental Objections and Responses to Dexcel Pharma Technologies Limited's First Set of Interrogatories (Nos. 1-3) filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 02/14/2025) | |
| 02/14/25 | Proposed Findings of Fact by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # [1] Exhibit 1, # [2] Exhibit 2, # [3] Exhibit 3, # [4] Exhibit 4)(Dudash, Amy) (Entered: 02/14/2025) |